drugset / Trial / NCT00673829
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to collect data on the safety and effectiveness of 2nd generation designer T cells in patients with breast cancer. Designer T cells are prepared by collecting white blood cells from the participant, and then modifying these cells in the laboratory so that they recognize the tumor antigen (CEA). These modified cells are then given back to the participant so that they can attack and kill tumor cells.
Timeline
- Start
- 2008-05
- Primary completion
- 2017-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gene Modified T Cells | Cell therapy | 1e+09 cells | Intravenous |
| Subject | Gene Modified T Cells | Cell therapy | 1e+10 cells | Intravenous |
| Subject | Gene Modified T Cells | Cell therapy | 1e+11 cells | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | — | — |